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Background
sJIA refractory to immunosuppressants including meth-
otrexate and TNF-a inhibitors can lead to severe dis-
abilities. Excessive IL-6 production has been implicated
in the pathoetiology of sJIA.
Aim
To determine the efficacy and safety of TCZ, an IL-6
receptor inhibitor, in patients (pts) with sJIA treated for
52 weeks (wks) in the ongoing, 3-part, 5-year, phase 3
TENDER study.
Methods
Pts (N=112) 2–17 years with active sJIA for ≥6m o n t h s
were randomized 2:1 to TCZ (8 mg/kg if body weight
≥30 kg; 12 mg/kg if <30 kg) or placebo every 2 wks for
12 wks in part 1; all pts received open-label (OL) TCZ
in part 2. Pts who escaped to OL TCZ in part 1 also
entered part 2. Oral corticosteroid (CS) tapering was
permitted at wks 6 and 8 in part 1 and in the OL exten-
sion in the presence of ACR70 response, ESR <20 mm/
h, and absence of fever. Efficacy data included pts who
reached wk 52 of TCZ treatment (n=88); safety data
considered all pts (N=112).
Results
Proportions of TCZ pts who achieved JIA ACR30 +
absence of fever or JIA ACR70/90 increased to wk 52
(Table). Number of joints with active arthritis or with
limitation of movement decreased from 19.8±15.7 and
19.8±15.6, respectively, to 3.0±7.0 and 7.5±11.7 at wk 52
(45% of pts had 0 active joints). CHAQ-DI score
improved from 1.7±0.9 to 0.7±0.8 at wk 52. Physician
global assessment VAS and pt/parent global assessment
VAS improved from 64.9±22.3 and 58.7±24.4, respec-
tively, to 9.7±12.8 and 12.6±18.5 at wk 52. CS dose
decreased from 0.30±0.20 mg/kg/d to 0.06±0.08 at wk 52;
48% discontinued CSs. 33 serious AEs (SAEs) occurred in
25 pts; 12 SAEs were considered related (remotely, possi-
bly, or probably) to TCZ (rate: 0.23/pt year [PY] in part
1, 0.25/PY in part 2). 15 serious infections occurred; 6
(gastroenteritis, varicella, septic arthritis, otitis media,
pharyngotonsillitis, upper respiratory tract infection)
were considered related to TCZ; all resolved and none
led to discontinuation. 12 pts withdrew (4, AEs; 4, insuffi-
cient response). One pt died of a suspected tension pneu-
mothorax considered unrelated to treatment.
Conclusions
TENDER 1-year results demonstrate that TCZ is highly
effective and generally well tolerated in pts with sJIA.
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Wk 12 Wk 52
Responses Placebo
(n=37)
TCZ
(n=75)
TCZ
(n=88)
JIA ACR30 + absence of fever,
n (%)
9 (24) 64 (85) 77 (88)
JIA ACR70, n (%) 3 (8) 53 (71) 78 (89)
JIA ACR90, n (%) 2 (5) 28 (37) 57 (65)
De Benedetti et al. Pediatric Rheumatology 2011, 9(Suppl 1):P164
http://www.ped-rheum.com/content/9/S1/P164
© 2011 De Benedetti et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Author details
1Ospedale Bambino Gesù, Rome, Italy.
2PRCSG, Cincinnati, USA.
3PRINTO,
Genoa, Italy.
4Roche, Welwyn, UK.
Published: 14 September 2011
doi:10.1186/1546-0096-9-S1-P164
Cite this article as: De Benedetti et al.: Efficacy and safety of tocilizumab
(TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender
52-week data. Pediatric Rheumatology 2011 9(Suppl 1):P164.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
De Benedetti et al. Pediatric Rheumatology 2011, 9(Suppl 1):P164
http://www.ped-rheum.com/content/9/S1/P164
Page 2 of 2